<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636515</url>
  </required_header>
  <id_info>
    <org_study_id>NTP-F520-006</org_study_id>
    <nct_id>NCT04636515</nct_id>
  </id_info>
  <brief_title>A Phase Ⅱ Study of F520 in Patients With Urothelial Carcinoma</brief_title>
  <official_title>A Phase 2, Open-label, Single-arm，Multicenter Study of F520 in Patients With Urothelial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong New Time Pharmaceutical Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong New Time Pharmaceutical Co., LTD</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, Phase 2 study to evaluate the efficacy and safety of the anti-&#xD;
      programmed cell death-1(PD-1) monoclonal antibody F520 in participants with locally advanced&#xD;
      or metastatic Urothelial Cancer (UC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by the investigator</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>ORR is defined as CR+PR</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Locally Advanced or Metastatic Urothelial Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F520</intervention_name>
    <description>200mg，Q3W</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed,locally advanced（T4b,any N or any T,N2-3 or&#xD;
             metastatic carcinoma（including renal pelvic, ureter bladder and urethra）;&#xD;
&#xD;
          2. Cohort 1：Patients with First-line platinum ineligible must meet criteria for either&#xD;
             option a or option b (below):&#xD;
&#xD;
               1. Has a tumor(s) with PD-L1 combined positive and is considered ineligible to&#xD;
                  receive cisplatin-based combination therapy, based on 1 of the following:&#xD;
&#xD;
                    -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 2&#xD;
                       within 7 days prior to randomization&#xD;
&#xD;
                    -  National Cancer Institute (NCI) Common Terminology Criteria for Adverse&#xD;
                       Events (CTCAE) Version 5.0 Grade ≥2 audiometric hearing loss&#xD;
&#xD;
                    -  NCI CTCAE Version 5.0 Grade ≥2 peripheral neuropathy OR&#xD;
&#xD;
               2. In the opinion of the investigator, is considered ineligible to receive any&#xD;
                  platinum-based chemotherapy (i.e., ineligible for cisplatin and carboplatin)&#xD;
                  based on:&#xD;
&#xD;
                    -  ECOG PS of 2 within 7 days prior to randomization. and ≥1 of the following:&#xD;
&#xD;
                    -  Documented visceral metastatic disease&#xD;
&#xD;
                    -  NCI CTCAE Version 5.0 Grade ≥2 audiometric hearing loss&#xD;
&#xD;
                    -  NCI CTCAE Version 5.0 Grade ≥2 peripheral neuropathy&#xD;
&#xD;
        Cohort 2: Inoperable Patients in sencond line（or beyond）with locally advanced or metastatic&#xD;
        urothelial carcinoma who have disease recurrence or progression during or after a&#xD;
        platinum-based chemotherapy regimen;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1&#xD;
&#xD;
          -  Calculated creatinine clearance ≥ 30 milliliter (mL)/min (Cockcroft-Gault formula)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has received prior therapy with an anti-PD-1, anti-PD-L1 agent or with CTLA-4&#xD;
             receptor;&#xD;
&#xD;
          2. Has a known hypersensitivity to anti-PD-1 / PD-L1 agent;&#xD;
&#xD;
          3. Known pia meningeal metastasis or active central nervous system (CNS) metastasis&#xD;
             revealed by CT or MRI. Participants with asymptomatic brain metastases may participate&#xD;
             without evidence of progression for at least 1 month.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

